Enanta Pharmaceuticals Inc (ENTA)

[floblu14]

ENANTA PHARMACEUTICALS INITIATES PHASE 1 CLINICAL STUDY OF EDP-297, ITS HIGHLY POTENT AND TARGETED FOLLOW-ON FARNESOID X RECEPTOR AGONIST FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
SEPTEMBER 14, 2020

-- Initial clinical data including safety, tolerability and pharmacokineticsexpected in 2Q 2021 –

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subjects in its Phase 1 clinical trial of EDP-297, a highly potent and targeted follow-on farnesoid X receptor (FXR) agonist, being developed for the treatment of non-alcoholic steatohepatitis (NASH).

“We are excited to advance our efforts in NASH and progress EDP-297, our follow-on FXR agonist, into clinical development,” commented Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “In preclinical studies, EDP-297 demonstrated a compelling product profile, with a potency greater than that published on any FXR agonist in clinical development and high target-tissue distribution in the liver and intestine. Based on these data, we believe we may be able to effectively dose EDP-297 at lower doses and with reduced drug levels in non-targeted tissues, potentially improving tolerability by reducing pruritis. We look forward to reporting clinical data in the second quarter of 2021.”

Read more:
https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Initiates-Phase-1-Clinical-Study-of-EDP-297-its-Highly-Potent-and-Targeted-Follow-On-Farnesoid-X-Receptor-Agonist-for-the-Treatment-of-Non-Alcoholic-Steatohepatitis/default.aspx